<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36712">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01759121</url>
  </required_header>
  <id_info>
    <org_study_id>S-PASCAL-PRP</org_study_id>
    <secondary_id>ChiCTR-TRC-12002735</secondary_id>
    <nct_id>NCT01759121</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR</brief_title>
  <acronym>S-PRP</acronym>
  <official_title>Randomized, Parallel Controlled, Clinical-trial on 532nm Laser Partially Subthreshold Panretinal Photocoagulation With PASCAL Endpoint Management Function for Severe Non-proliferative Diabetic Retinopathy(NPDR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic
      efficacy of 532nm laser partially subthreshold panretinal photocoagulation with PASCAL
      endpoint management function for severe non-proliferative diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic
      efficacy of 532nm laser partially subthreshold panretinal photocoagulation with PASCAL
      endpoint management function for severe non-proliferative diabetic retinopathy : (1)To
      evaluate therapeutic effect of 532nm laser partially subthreshold panretinal
      photocoagulation with PASCAL endpoint management function for severe non-proliferative
      diabetic retinopathy; (2)To compare side effect of 532nm laser partially subthreshold
      panretinal photocoagulation with PASCAL endpoint management function on retina with
      traditional visible endpoint panretinal photocoagulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change of best corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>best corrected visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the probability of vitreous haemorrhage</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Retinal Thickness</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>foveal volume of macula</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of microaneurysms</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of bard exudate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of retinal hemorrhage</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount and area of IRMA</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of neovascularization</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of ischemia area</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Severe Non-proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>T-PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>532nm-short pulse panretinal photocoagulation with PASCAL function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>T-PRP</intervention_name>
    <description>532nm-short pulse panretinal photocoagulation with PASCAL function</description>
    <arm_group_label>T-PRP</arm_group_label>
    <other_name>Traditional-PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>S-PRP</intervention_name>
    <description>532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function</description>
    <arm_group_label>S-PRP</arm_group_label>
    <other_name>Subthreshold PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of severe non-proliferative diabetic retinopathy

          -  Age:45-80 years

          -  Best corrected visual acuity(BCVA) ≥20/100,Myopia≤-6 degree(-6D)

          -  No photocoagulation (PRP) before this clinical trial and no major ocular surgery
             (including cataract extraction, or any other intraocular surgery) within 3 months

          -  Ability and willingness to provide informed consent

        Exclusion Criteria:

          -  Participate in other clinical trials within 3 months

          -  Severe refractive media turbidity; Unable to accept laser treatment such as
             nystagmus, etc

          -  Medically or mentally unstable(including cardiovascular disorders, cerebrovascular
             diseases,liver and kidney disease,hematological disorder and psychosis

          -  Conditions that in the opinion of the investigator would interfere trial results or
             increase risk

          -  Conditions that in the opinion of the investigator would preclude participation in
             the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-jin Jin</last_name>
    <role>Study Director</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pei-pei Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei-pei Wu</last_name>
    <phone>13602457876</phone>
    <email>ree04@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peipei Wu</last_name>
      <phone>13602457876</phone>
      <email>ree04@126.com</email>
    </contact>
    <investigator>
      <last_name>Chen-jin Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peipei Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nature.com/eye/journal/v22/n5/full/6702725a.html</url>
    <description>a clinical study on subthreshold panretinal photocoagulation for proliferative diabetic retinopathy (PDR)</description>
  </link>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>January 1, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jin Chen-jin</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>severe non-proliferative diabetic retinopathy</keyword>
  <keyword>subthreshold</keyword>
  <keyword>panretinal photocoagulation</keyword>
  <keyword>PASCAL</keyword>
  <keyword>endpoint management</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
